XNCR | Ticker Profile - Titan Protect

XNCR

Xencor, Inc.

Healthcare · Biotechnology · NGM

$11.77

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$869M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.29

Based on estimated future earnings — lower means cheaper

Rev Growth

-86.2%

Year-over-year revenue change

Profit Margin

-177.1%

How much profit the company keeps from each dollar of revenue

ROE

-29.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$28.00

+138% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 12 analysts covering this stock

About Xencor, Inc.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

https://www.xencor.com

Country: United States Employees: 260 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.204

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0285

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.383

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-28.3%

Historical annualised return based on price data

Max Drawdown

-73.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.93

Less volatile than the market — more defensive

52W High

$18.69

37% below the year high

52W Low

$6.92

70% above the year low

Avg Volume

844,368

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

20.5%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.29

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

33.97

Heavy leverage — higher financial risk if revenues decline

Current Ratio

6.57

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.22

Like current ratio but excludes inventory — stricter test

Gross Margin

-152.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,724.1%

Profit from core operations before interest and tax

Free Cash Flow

$-76,885,376

Negative — the business is spending more than it generates

Revenue (TTM)

$97M

Total revenue over the last 12 months

Net Income

$-172,420,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$43.00

Target Median

$28.00

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go